Novo Nordisk recorded a sharp stock surge of up to 6% following the release of third-quarter financial results that surpassed market expectations. The positive performance was significantly propelled by robust international demand for its GLP-1 weight-loss medications, particularly the oral Wegovy pill, which generated 5.4 billion Danish kroner ($775 million) in sales, easily beating projections. Total quarterly revenue reached 79.2 billion Danish kroner ($11.9 billion), representing a 4% year-over-year increase at constant exchange rates, while adjusted operating profit finished at 31.7 billion kroner.

Encouraged by the strong quarterly metrics, the Danish pharmaceutical enterprise updated its full-year financial guidance. Novo now anticipates full-year adjusted revenue and operating profit growth to range between negative 2% and positive 2% at constant exchange rates. This revision represents a significant upgrade from its previous forecast of negative 6% to flat growth. The enterprise maintained an 80% market share in the United States GLP-1 space, despite escalating competition from rival Eli Lilly. During the quarter, sales of injectable Wegovy reached 20.4 billion kroner, while diabetes medication Ozempic brought in 29.7 billion kroner.

The strong financial results come as Novo works to restore investor confidence following a turbulent period in which Eli Lilly captured market share in the United States with its treatments Mounjaro and Zepbound. Industry observers are heavily focused on the next generation of weight-loss therapies, including Novo’s candidate CagriSema, a combination drug aimed at addressing obesity as well as related cardiovascular, kidney, and metabolic conditions. However, market observers continue to monitor potential pricing pressures and long-term successor viability across the sector.

In tandem with its financial updates, Novo announced an upcoming shift in executive leadership. Chief Financial Officer Karsten Munk Knudsen will step down at the end of 2026 after 27 years with the organization, including nine years as CFO. Luigi La Corte, current CFO of Swiss dermatology company Galderma, has been named as his successor. Company leadership emphasized that while one solid quarter does not mark a complete turnaround, the upwardly revised outlook confirms that the firm is heading in a positive direction.

Key Takeaways

• Novo beat third-quarter expectations with revenue reaching 79.2 billion Danish kroner, driven by strong sales of the Wegovy oral pill.
• The company upgraded its full-year guidance for adjusted revenue and operating profit growth to between -2% and 2%.
• Novo announced that long-serving CFO Karsten Munk Knudsen will retire at the end of 2026 and be succeeded by Luigi La Corte.

Editor’s Analysis & Impact

Novo’s latest financial results demonstrate notable resilience within the rapidly expanding GLP-1 sector. By beating revenue projections and lifting its annual forecast, the firm has signaled a stabilization in its competitive battle against Eli Lilly. The strong market adoption of the Wegovy pill underscores the strategic necessity of offering alternative delivery formats to capture broader patient groups. Nevertheless, long-term headwinds persist. Pricing pressure in key markets like the United States remains an ongoing hurdle, and clinical questions regarding next-generation candidates such as CagriSema persist. To maintain its market position, Novo must successfully navigate its executive transition and demonstrate the commercial viability of its future pipeline.

Frequently Asked Questions

Q: Why did Novo's stock price jump after the quarterly report?
A: The stock surged after Novo reported third-quarter revenue and operating profit that exceeded market expectations, driven largely by high demand for its Wegovy pill and Ozempic treatments.

Q: What is Novo's updated full-year financial outlook?
A: Novo now expects full-year adjusted revenue and operating profit growth to range between negative 2% and positive 2% at constant exchange rates, up from a previous forecast of negative 6% to flat.

Q: Who will be taking over as Chief Financial Officer at Novo?
A: Luigi La Corte, currently the CFO of Swiss dermatology firm Galderma, will succeed Karsten Munk Knudsen when he steps down at the end of 2026.